aiwiki.page
English
Health / Diseases & Symptoms / chronic-inflammatory-demyelinating-polyneuropathy

Chronic inflammatory demyelinating polyneuropathy

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated peripheral nerve disorder causing progressive or relapsing weakness, sensory loss, and reduced reflexes.

25 keywords2 linked from2 not yet writtenWritten by AI
Peripheral Nervo…Immune SystemSchwann CellDemyelinationCentral Nervous…Multiple Scleros…ReflexFatigueChronic in…

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated disorder of the peripheral nervous system characterized by progressive or relapsing muscle weakness, sensory impairment, and reduced or absent tendon reflexes. Its typical form develops over at least eight weeks and affects both sides of the body. Injury to the insulating myelin around peripheral nerve fibers disrupts electrical signaling; additional damage to the nerve fibers themselves can cause lasting disability. CIDP is a treatable disorder, but its presentation, response to treatment, and long-term course vary considerably.

Mechanisms and pathology

CIDP involves abnormal activity of the immune system directed against peripheral nerves and nerve roots. Both cellular and antibody-mediated mechanisms have been implicated, although the initiating cause and precise immune targets remain unidentified in most patients.

Peripheral myelin is produced by Schwann cells. Loss or damage of this covering, termed demyelination, slows nerve impulse conduction and may prevent impulses from passing through affected nerve segments. Repeated demyelination and repair can produce characteristic structural changes, including concentric layers of Schwann-cell processes known as onion bulbs. These findings are not unique to CIDP.

Damage to axons—the long processes of nerve cells—can develop alongside demyelination. Axonal loss is an important determinant of persistent weakness, muscle wasting, and incomplete recovery, even when immune activity has been controlled.

CIDP primarily affects peripheral nerves rather than the central nervous system. It is therefore distinct from multiple sclerosis, despite both disorders involving myelin injury.

Clinical presentation and variants

Typical CIDP

Typical CIDP produces relatively symmetrical weakness in both proximal muscles, such as those around the shoulders and hips, and distal muscles, such as those in the hands and feet. Common manifestations include:

  • Difficulty climbing stairs, rising from a chair, walking, or performing fine hand movements.
  • Numbness, tingling, and reduced sensation in the limbs.
  • Impaired position sense, which can contribute to unsteadiness.
  • Reduced or absent tendon reflexes.
  • Fatigue and, in some patients, neuropathic pain.

Symptoms may worsen steadily, fluctuate, or occur as relapses separated by periods of improvement. Cranial nerve involvement can occur, but prominent respiratory failure or severe autonomic dysfunction is unusual and may suggest another diagnosis.

CIDP variants

Recognized variants differ in the distribution or type of nerve dysfunction:

  • Distal CIDP: sensory loss and weakness predominate in the distal limbs, often more prominently in the legs.
  • Multifocal CIDP: deficits are asymmetrical and involve several peripheral nerve territories. This presentation is also called Lewis–Sumner syndrome or multifocal acquired demyelinating sensory and motor neuropathy.
  • Focal CIDP: abnormalities are restricted to one limb or a limited region.
  • Motor CIDP: weakness predominates without clinical sensory involvement.
  • Sensory CIDP: sensory dysfunction predominates without clinical weakness.

These categories require careful clinical and electrophysiological assessment because similar patterns occur in other neuropathies.

Autoimmune nodopathies

Some patients with a CIDP-like illness have antibodies against proteins at or near the nodes of Ranvier, where nerve impulses are regenerated. Targets include neurofascin-155, contactin-1, and contactin-associated protein 1.

Current classifications distinguish these disorders as autoimmune nodopathies, rather than conventional CIDP. Their mechanisms, associated features, and treatment responses can differ; some respond poorly to standard immunoglobulin treatment.

Diagnosis

CIDP has no single definitive diagnostic test. Diagnosis combines the clinical pattern and time course with evidence of peripheral nerve demyelination, while excluding alternative explanations.

Nerve conduction studies

Nerve conduction studies are central to diagnosis. Findings supporting demyelination include substantially slowed conduction velocities, prolonged distal motor latencies, delayed or absent F waves, conduction block, and abnormal temporal dispersion.

Formal criteria specify the degree and distribution of these abnormalities. Mild slowing alone is insufficient: low temperature, compression at common nerve entrapment sites, and axonal loss can produce findings that resemble demyelination. Needle electromyography can provide additional information about axonal injury.

Supportive investigations

Additional investigations may strengthen a diagnosis or identify another cause:

  • Cerebrospinal fluid analysis: increased cerebrospinal fluid protein with a normal or near-normal white-cell count is supportive but not specific. Protein concentrations also vary with age and other conditions.
  • Imaging: ultrasonography or magnetic resonance imaging may show enlargement of peripheral nerves, nerve roots, or plexuses. Such abnormalities are not diagnostic by themselves.
  • Blood testing: investigations can identify metabolic, nutritional, infectious, or protein-related disorders that mimic CIDP.
  • Nerve biopsy: biopsy is not routinely required. It may be used in selected unresolved cases, particularly when another disorder is suspected.
  • Objective treatment response: documented improvement in strength or function can provide supporting evidence in an appropriate clinical context, but subjective improvement alone does not establish CIDP.

Differential diagnosis and diagnostic limitations

An important distinction is from Guillain–Barré syndrome, which usually reaches its greatest severity within four weeks. A minority of patients with CIDP initially develop symptoms rapidly; continued progression or subsequent relapses can reveal an acute-onset CIDP course.

Other conditions considered in the differential diagnosis include inherited demyelinating neuropathies, multifocal motor neuropathy, amyloid neuropathy, vasculitic neuropathy, and neuropathies associated with diabetes mellitus, vitamin B12 deficiency, or abnormal monoclonal proteins. Distal neuropathy associated with antibodies to myelin-associated glycoprotein is generally distinguished from CIDP.

Misdiagnosis is a recognized problem. Common sources of error include overinterpreting mildly elevated cerebrospinal fluid protein, treating nonspecific nerve conduction abnormalities as proof of demyelination, and relying on perceived benefit from treatment without objective functional change. Conversely, unusual distributions of weakness or sensory loss can delay recognition of genuine CIDP.

Treatment

Treatment aims to suppress immune-mediated nerve injury, improve function, and prevent further disability. The strongest established evidence supports immunoglobulin therapy, corticosteroids, and plasma exchange.

  • Immunoglobulin: intravenous immunoglobulin can improve strength and disability and is used for initial and maintenance treatment. Subcutaneous immunoglobulin is an established maintenance option in patients who respond to immunoglobulin.
  • Corticosteroids: corticosteroids can improve disease activity and sometimes produce sustained remission. Their long-term use is limited by adverse effects, including metabolic complications, infection risk, and bone loss. Motor CIDP is a special consideration because deterioration with corticosteroids has been reported.
  • Plasma exchange: this form of apheresis removes circulating plasma components and can produce relatively rapid improvement. Benefits may be temporary, and repeated treatment may be necessary.

Other immune-modifying treatments are used in selected circumstances, although the strength of supporting evidence varies by drug and patient subgroup.

Treatment response is assessed using measures such as muscle strength, grip strength, walking ability, and disability scales. Periodic reassessment helps distinguish ongoing immune activity from fixed nerve damage and establish whether maintenance treatment remains necessary.

Rehabilitation, including physical and occupational therapy, addresses weakness, impaired balance, limitations in daily activities, and the consequences of residual nerve injury. Supportive care may also address neuropathic pain and fatigue.

Epidemiology and prognosis

CIDP is uncommon. Published prevalence estimates vary substantially because studies use different diagnostic criteria and methods of case identification. It occurs in children and adults, but is more frequent in older adults and is reported more often in males.

The prognosis is variable. Some patients achieve prolonged remission without ongoing treatment, whereas others have a relapsing course or require long-term maintenance therapy. Persistent disability can reflect irreversible axonal loss rather than continuing inflammation. Disease activity, treatment dependence, and accumulated nerve damage are therefore distinct aspects of long-term assessment.